Ocular Hypertension Completed Phase 2 Trials for Travoprost (DB00287)

Also known as: Intraocular pressure raised / Ocular Hypertension (OHT) / Hypertension Ocular / Hypertension, Ocular / Intraocular pressure high / Intraocular hypertension / Ocular Hypertension (OH) / Elevated intraoccular pressure / Intraocular pressure increased / IOP increased / Raised IOP / Ocular tension increased / Tension ocular increased / Pressure intraocular increased / Increased intraocular pressure

IndicationStatusPhase
DBCOND0074237 (Ocular Hypertension)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT021400606-Week Proof-of-Concept Study of Travoprost/Brinzolamide Ophthalmic Suspension in Subjects With Open-Angle Glaucoma or Ocular HypertensionTreatment
NCT00637130Safety and Intraocular Pressure (IOP) Lowering Efficacy of Low Dose TravoprostTreatment
NCT00527501IOP Lowering Efficacy of Travoprost/Brinzolamide Fixed Combination Ophthalmic Suspension in Patients With Open-Angle Glaucoma or Ocular HypertensionTreatment
NCT01254370Safety and Efficacy Study of Catioprost® (Unpreserved Latanoprost 0.005% Emulsion) Compared to Travatan Z® to Treat Glaucoma and Ocular Surface DiseaseTreatment
NCT01474135AR-12286 Fixed Dose Combination to Lower Elevated Intraocular PressureTreatment
NCT01789736A Study Assessing PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components for 28 DaysTreatment
NCT01298687Divided Dose of TRAVATAN®Treatment
NCT01114893Travoprost Five Day Posology StudyTreatment
NCT00670033Travoprost New Formulations in Patients With Open-Angle Glaucoma or Ocular HypertensionTreatment